<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37200354</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>5</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Clinical characterization of a cohort of patients treated for systemic lupus erythematosus in Colombia: A retrospective study.</ArticleTitle><Pagination><StartPage>e0285889</StartPage><MedlinePgn>e0285889</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0285889</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0285889</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Systemic lupus erythematosus is an autoimmune disease associated with serious complications and high costs. The aim was to describe the clinical characteristics and health care resource utilization of a Colombian systemic lupus erythematosus outpatient cohort.</AbstractText><AbstractText Label="METHODS">This was a retrospective descriptive study. Clinical records and claims data for systemic lupus erythematosus patients from ten specialized care centers in Colombia were reviewed for up to 12 months. Baseline clinical variables, Systemic Lupus Erythematosus Disease Activity Index, drug use, and direct costs were measured. Descriptive statistics were analyzed using SPSS.</AbstractText><AbstractText Label="RESULTS">A total of 413 patients were included; 361 (87.4%) were female, and the mean age was 42 &#xb1; 14 years. The mean disease evolution was 8.9 &#xb1; 6.0 years; 174 patients (42.1%) had a systemic manifestation at baseline, mostly lupus nephritis (105; 25.4%). A total of 334 patients (80.9%) had at least one comorbidity, mainly antiphospholipid syndrome (90; 21.8%) and hypertension (76; 18.4%). The baseline Systemic Lupus Erythematosus Disease Activity Index score was 0 in 215 patients (52.0%), 1-5 in 154 (37.3%), 6-10 in 41 (9.9%) and 11+ in 3 (0.7%). All patients received pharmacological therapy, and the most common treatment was corticosteroids (293; 70.9%), followed by antimalarials (chloroquine 52.5%, hydroxychloroquine 31.0%), immunosuppressants (azathioprine 45.3%, methotrexate 21.5%, mycophenolate mofetil 20.1%, cyclosporine 8.0%, cyclophosphamide 6.8%, leflunomide 4.8%) and biologicals (10.9%). The mean annual costs were USD1954 per patient/year, USD1555 for antirheumatic drugs (USD10,487 for those with biologicals), USD86 for medical visits, USD235 for drug infusions and USD199 for laboratory tests.</AbstractText><AbstractText Label="CONCLUSIONS">Systemic lupus erythematosus generates an important economic and morbidity burden for the Colombian health system. Systemic lupus erythematosus outpatient attention costs in the observation year were mainly determined by drug therapy (especially biologics), medical visits and laboratory tests. New studies addressing the rate of exacerbations, long-term follow-up or costs related to hospital care are recommended.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2023 Machado-Alba et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Machado-Alba</LastName><ForeName>Jorge Enrique</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0002-8455-0936</Identifier><AffiliationInfo><Affiliation>Grupo de Investigaci&#xf3;n de Farmacoepidemiolog&#xed;a y Farmacovigilancia, Universidad Tecnol&#xf3;gica de Pereira - Audifarma SA, Pereira, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machado-Duque</LastName><ForeName>Manuel E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Grupo de Investigaci&#xf3;n de Farmacoepidemiolog&#xed;a y Farmacovigilancia, Universidad Tecnol&#xf3;gica de Pereira - Audifarma SA, Pereira, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Grupo de Investigaci&#xf3;n Biomedicina, Facultad de Medicina, Fundaci&#xf3;n Universitaria Autonoma de las Am&#xe9;ricas, Pereira, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaviria-Mendoza</LastName><ForeName>Andres</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2500-7658</Identifier><AffiliationInfo><Affiliation>Grupo de Investigaci&#xf3;n de Farmacoepidemiolog&#xed;a y Farmacovigilancia, Universidad Tecnol&#xf3;gica de Pereira - Audifarma SA, Pereira, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Grupo de Investigaci&#xf3;n Biomedicina, Facultad de Medicina, Fundaci&#xf3;n Universitaria Autonoma de las Am&#xe9;ricas, Pereira, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Rey</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline, Medical Pharma, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Rangel</LastName><ForeName>Andr&#xe9;s</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8835-0635</Identifier><AffiliationInfo><Affiliation>GlaxoSmithKline, Medical Pharma, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003105" MajorTopicYN="N" Type="Geographic">Colombia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>This was a GSK sponsored study (ID 207051). GSK was involved in protocol development, study oversight and manuscript review previous to submission. GSK did not participate in data collection, analysis or interpretation, or the drafting of this article. Authors CDR and AGR are GSK employees. Authors JMA, MMD and AGM declare no other competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>18</Day><Hour>19</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>18</Day><Hour>13</Hour><Minute>45</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37200354</ArticleId><ArticleId IdType="pmc">PMC10194955</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0285889</ArticleId><ArticleId IdType="pii">PONE-D-22-14695</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Thong B, Olsen NJ. Systemic lupus erythematosus diagnosis and management. Rheumatology (Oxford). 2017;56(suppl_1):i3&#x2013;i13. doi: 10.1093/rheumatology/kew401</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew401</ArticleId><ArticleId IdType="pubmed">28013206</ArticleId></ArticleIdList></Reference><Reference><Citation>Golder V, Hoi A. Systemic lupus erythematosus: an update. Med J Aust. 2017;206(5):215&#x2013;220. doi: 10.5694/mja16.01229</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/mja16.01229</ArticleId><ArticleId IdType="pubmed">28301792</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010;39(4):257&#x2013;68. doi: 10.1016/j.semarthrit.2008.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2008.10.007</ArticleId><ArticleId IdType="pmc">PMC2813992</ArticleId><ArticleId IdType="pubmed">19136143</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-&#xc1;vila DG, Bernal-Mac&#xed;as S, Rinc&#xf3;n-Ria&#xf1;o DN, Guti&#xe9;rrez D&#xe1;vila JM, Rosselli D. Prevalence of systemic lupus erythematosus in Colombia: data from the national health registry 2012&#x2013;2016. Lupus. 2019;28(10):1273&#x2013;8. doi: 10.1177/0961203319864168</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319864168</ArticleId><ArticleId IdType="pubmed">31354025</ArticleId></ArticleIdList></Reference><Reference><Citation>Haase I, Mucke J, Chehab G, Fischer-Betz R, Schneider M, Brinks R. Incidence of systemic lupus erythematosus in Colombia: data from the National Health Registry 2012&#x2013;2016. Lupus. 2019;28(13):1610&#x2013;1. doi: 10.1177/0961203319878498</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319878498</ArticleId><ArticleId IdType="pmc">PMC6851534</ArticleId><ArticleId IdType="pubmed">31581893</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha JS, Gilek-Seibert K. Systemic Lupus Erythematosus: A Review of the Clinical Approach to Diagnosis and Update on Current Targeted Therapies. R I Med J (2013). 2016;99(12):23&#x2013;27</Citation><ArticleIdList><ArticleId IdType="pubmed">27902995</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinmann JF, Tubach F, Le Guern V, Mathian A, Richez C, Saadoun D, et al.. International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmun Rev. 2017;16(6):650&#x2013;657. doi: 10.1016/j.autrev.2017.04.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2017.04.011</ArticleId><ArticleId IdType="pubmed">28434948</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro Castro S, Isenberg DA. Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness. Ther Adv Musculoskelet Dis. 2017;9(3):75&#x2013;85. doi: 10.1177/1759720X17690474</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1759720X17690474</ArticleId><ArticleId IdType="pmc">PMC5349337</ArticleId><ArticleId IdType="pubmed">28344669</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo-Alen J, Silva-Fernandez L, Ucar-Angulo E, Pego-Reigosa JM, Olive A, Martinez-Fernandez C, et al.. SER consensus statement on the use of biologic therapy for systemic lupus erythematosus. Reumatol Clin. 2013;9(5):281&#x2013;96. doi: 10.1016/j.reuma.2013.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reuma.2013.04.001</ArticleId><ArticleId IdType="pubmed">23871156</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xed;os-Garc&#xe9;s R, Espinosa G, van Vollenhoven R, Cervera R. Treat-to-target in systemic lupus erythematosus: Where are we? Eur J Intern Med. 2020;74:29&#x2013;34. doi: 10.1016/j.ejim.2020.01.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2020.01.018</ArticleId><ArticleId IdType="pubmed">32014364</ArticleId></ArticleIdList></Reference><Reference><Citation>Ariza K, Isaza P, Gaviria AM, Quiceno JM, Vinaccia S, Alvar&#xe1;n L, et al.. Calidad de vida relacionada con la salud, factores psicol&#xf3;gicos y fisiopatol&#xf3;gicos en pacientes con diagn&#xf3;stico de Lupus Eritematoso Sist&#xe9;mico-LES. Terapia psicol&#xf3;gica. 2010;28(1):27&#x2013;36. doi: 10.4067/S0718-48082010000100003</Citation><ArticleIdList><ArticleId IdType="doi">10.4067/S0718-48082010000100003</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco CJV, N&#xfa;&#xf1;ez JJY, Mendoza KLA, Arenas PAI, G&#xf3;mez AMG, Mu&#xf1;oz-Grajales C, et al.. Estimaci&#xf3;n de la calidad de vida relacionada con la salud y medidas de utilidad en una poblaci&#xf3;n de pacientes colombianos con lupus eritematoso sist&#xe9;mico. Rev Colomb Reumatol. 2013;20(4):183&#x2013;94. doi: 10.1016/S0121-8123(13)70132-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0121-8123(13)70132-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina JE, Mora C, Jaimes DA, Arbel&#xe1;ez AM, Valencia Toro PA, Salazar RE, et al.. Valoraci&#xf3;n de la actividad, del da&#xf1;o cr&#xf3;nico y alteraci&#xf3;n de la calidad de vida en una cohorte de pacientes colombianos con lupus eritematoso sist&#xe9;mico por medio de SELENA-SLEDAI, BILAG 2004, SLICC/ACR y SF-36. Rev Colomb Reumatol. 2013;20(4):211&#x2013;7. doi: 10.1016/S0121-8123(13)70135-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0121-8123(13)70135-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Prada S, Perez A, Nieto-Aristiz&#xe1;bal I, Tob&#xf3;n G. Direct cost of lupus care in the developing world: the case of Colombia. Lupus. 2019;28(8):970&#x2013;6. doi: 10.1177/0961203319856093</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319856093</ArticleId><ArticleId IdType="pubmed">31204587</ArticleId></ArticleIdList></Reference><Reference><Citation>Londo&#xf1;o J, Pel&#xe1;ez-Ballestas I, Cuervo F, Angarita I, Giraldo R, Rueda JC, et al.. Prevalencia de la enfermedad reum&#xe1;tica en Colombia, seg&#xfa;n estrategia COPCORD-Asociaci&#xf3;n Colombiana de Reumatolog&#xed;a. Estudio de prevalencia de enfermedad reum&#xe1;tica en poblaci&#xf3;n colombiana mayor de 18 a&#xf1;os. Rev Colomb Reumatol. 2018;25:245&#x2013;56. doi: 10.1016/j.rcreu.2018.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rcreu.2018.08.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Decreto 2423 de 2006, actualizado a 2018. Por el cual se determina la nomenclatura y clasificaci&#xf3;n de los procedimientos m&#xe9;dicos, quir&#xfa;rgicos y hospitalarios del Manual Tarifario y se dictan otras disposiciones. Bogot&#xe1;, Colombia (2018). [Access: 1 June 2022]. www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/decreto-2423-de-1996.pdf</Citation></Reference><Reference><Citation>Sullivan KM, Dean A, Soe MM. On academics: OpenEpi: a web-based epidemiologic and statistical calculator for public health. Public health reports. 2009;124(3):471&#x2013;4. doi: 10.1177/003335490912400320</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/003335490912400320</ArticleId><ArticleId IdType="pmc">PMC2663701</ArticleId><ArticleId IdType="pubmed">19445426</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajian-Tilaki K. Sample size estimation in epidemiologic studies. Caspian J Intern Med. 2011;2(4):289&#x2013;98</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3895825</ArticleId><ArticleId IdType="pubmed">24551434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministerio de Salud. Resoluci&#xf3;n 8430 de 1993. Bogot&#xe1; D.C. Colombia.</Citation></Reference><Reference><Citation>Tanaka Y, Mizukami A, Kobayashi A, Ito C, Matsuki T. Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study. Int J Rheum Dis. 2018;21(8):1609&#x2013;1618. doi: 10.1111/1756-185X.13363</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.13363</ArticleId><ArticleId IdType="pmc">PMC6585770</ArticleId><ArticleId IdType="pubmed">30146745</ArticleId></ArticleIdList></Reference><Reference><Citation>Kent T, Davidson A, Newman D, Buck G, D&#x2019;Cruz D. Burden of illness in systemic lupus erythematosus: results from a UK patient and carer online survey. Lupus. 2017;26(10):1095&#x2013;1100. doi: 10.1177/0961203317698594</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317698594</ArticleId><ArticleId IdType="pubmed">28406053</ArticleId></ArticleIdList></Reference><Reference><Citation>Santamaria-Alza Y, Motta JZN, Fajardo-Rivero JE, Pineda CLF. Systemic lupus erythematosus, gender differences in Colombian patients. Clin Rheumatol. 2018;37(9):2423&#x2013;2428. doi: 10.1007/s10067-018-4161-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-018-4161-8</ArticleId><ArticleId IdType="pubmed">29860566</ArticleId></ArticleIdList></Reference><Reference><Citation>Severiche Maury DM, Restrepo Escobar M, Gonz&#xe1;lez Naranjo LA, Vanegas Garc&#xed;a AL, Mu&#xf1;oz Vahos CH, V&#xe1;squez Duque GM. Ciento quince pacientes con lupus eritematoso sist&#xe9;mico: caracter&#xed;sticas cl&#xed;nicas e inmunol&#xf3;gicas. Rev Colomb Reumatol. 2014;21(4):183&#x2013;92. doi: 10.1016/j.rcreu.2014.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rcreu.2014.10.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Essouma M, Nkeck JR, Endomba FT, Bigna JJ, Singwe-Ngandeu M, Hachulla E. Systemic lupus erythematosus in Native sub-Saharan Africans: A systematic review and meta-analysis. J Autoimmun. 2020;106:102348. doi: 10.1016/j.jaut.2019.102348</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2019.102348</ArticleId><ArticleId IdType="pubmed">31668352</ArticleId></ArticleIdList></Reference><Reference><Citation>Elera-Fitzcarrald C, Fuentes A, Gonzalez LA, Burgos PI, Alarcon GS, Ugarte-Gil MF. Factors affecting quality of life in patients with systemic lupus erythematosus: important considerations and potential interventions. Expert Rev Clin Immunol. 2018;14(11):915&#x2013;931. doi: 10.1080/1744666X.2018.1529566</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2018.1529566</ArticleId><ArticleId IdType="pubmed">30266076</ArticleId></ArticleIdList></Reference><Reference><Citation>Ocampo-Piraquive V, Nieto-Aristizabal I, Canas CA, Tobon GJ. Mortality in systemic lupus erythematosus: causes, predictors and interventions. Expert Rev Clin Immunol. 2018;14(12):1043&#x2013;1053. doi: 10.1080/1744666X.2018.1538789</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2018.1538789</ArticleId><ArticleId IdType="pubmed">30338717</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al.. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67(2):195&#x2013;205. doi: 10.1136/ard.2007.070367</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2007.070367</ArticleId><ArticleId IdType="pubmed">17504841</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D&#x2019;Cruz D, et al.. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford). 2018;57(1):e1&#x2013;e45. doi: 10.1093/rheumatology/kex286</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex286</ArticleId><ArticleId IdType="pubmed">29029350</ArticleId></ArticleIdList></Reference><Reference><Citation>Khamashta MA, Bruce IN, Gordon C, Isenberg DA, Ateka-Barrutia O, Gayed M, et al.. The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease. Lupus. 2014;23(3):273&#x2013;83. doi: 10.1177/0961203313517407</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313517407</ArticleId><ArticleId IdType="pubmed">24356612</ArticleId></ArticleIdList></Reference><Reference><Citation>Kan HJ, Song X, Johnson BH, Bechtel B, O&#x2019;Sullivan D, Molta CT. Healthcare utilization and costs of systemic lupus erythematosus in Medicaid. Biomed Res Int. 2013;2013:808391. doi: 10.1155/2013/808391</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/808391</ArticleId><ArticleId IdType="pmc">PMC3591216</ArticleId><ArticleId IdType="pubmed">23484162</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu MM, Wang XP, Cheng QY, Zhao YL, Zhang TP, Li BZ, et al.. A Meta-Analysis of Cardiovascular Events in Systemic Lupus Erythematosus. Immunol Invest. 2019;48(5):505&#x2013;20. doi: 10.1080/08820139.2019.1567534</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08820139.2019.1567534</ArticleId><ArticleId IdType="pubmed">30961407</ArticleId></ArticleIdList></Reference><Reference><Citation>Han GM, Han XF. Comorbid Conditions are Associated With Emergency Department Visits, Hospitalizations, and Medical Charges of Patients With Systemic Lupus Erythematosus. J Clin Rheumatol. 2017;23(1):19&#x2013;25. doi: 10.1097/RHU.0000000000000437</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000000437</ArticleId><ArticleId IdType="pubmed">28002152</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyagawa I, Nakano K, Nakayamada S, Iwata S, Hanami K, Fukuyo S, et al.. Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus. Int J Rheum Dis. 2019;22(3):434&#x2013;42. doi: 10.1111/1756-185X.13387</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.13387</ArticleId><ArticleId IdType="pubmed">30338639</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang ASMW Bultink IE. Systemic lupus erythematosus: review of synthetic drugs. Expert Opin Pharmacother. 2015;16(18):2793&#x2013;806. doi: 10.1517/14656566.2015.1101448</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656566.2015.1101448</ArticleId><ArticleId IdType="pubmed">26479437</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakthiswary R, Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus. 2014;23(3):225&#x2013;35. doi: 10.1177/0961203313519159</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313519159</ArticleId><ArticleId IdType="pubmed">24399812</ArticleId></ArticleIdList></Reference><Reference><Citation>Kan H, Nagar S, Patel J, Wallace DJ, Molta C, Chang DJ. Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus. Clin Ther. 2016;38(3):610&#x2013;24. doi: 10.1016/j.clinthera.2016.01.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2016.01.016</ArticleId><ArticleId IdType="pubmed">26907503</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministerio de Salud y Protecci&#xf3;n Social. Resoluci&#xf3;n N&#xfa;mero 006411 de 2016, Valor de la Unidad de Pago por Capitaci&#xf3;n (UPC) vigencia de 2017 (2016). [Access 01 Sep 2021]. https://www.minsalud.gov.co/Normatividad_Nuevo/Resoluci%C3%B3n%206411%20de%202016.pdf</Citation></Reference><Reference><Citation>Zhu TY, Tam LS, Li EK. Cost&#x2010;of&#x2010;illness studies in systemic lupus erythematosus: A systematic review. Arthritis Care Res (Hoboken). 2011;63(7):1074. doi: 10.1002/acr.20410</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.20410</ArticleId><ArticleId IdType="pubmed">21557530</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke AE, Petri MA, Manzi S, Isenberg DA, Gordon C, Senecal JL, et al.. An international perspective on the well being and health care costs for patients with systemic lupus erythematosus. Tri-Nation Study Group. J Rheumatol. 1999;26(7):1500&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">10405937</ArticleId></ArticleIdList></Reference><Reference><Citation>Doria A, Amoura Z, Cervera R, Khamastha MA, Schneider M, Richter J, et al.. Annual direct medical cost of active systemic lupus erythematosus in five European countries. Ann Rheum Dis. 2014;73(1):154&#x2013;60. doi: 10.1136/annrheumdis-2012-202443</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202443</ArticleId><ArticleId IdType="pubmed">23264339</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy O, Markov A, Drob Y, Maslakov I, Tishler M, Amit-Vazina M. All-cause hospitalizations in systemic lupus erythematosus from a single medical center in Israel. Rheumatol Int. 2018;38(10):1841&#x2013;6. doi: 10.1007/s00296-018-4147-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-018-4147-5</ArticleId><ArticleId IdType="pubmed">30151719</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>